Mo­men­ta hit with a set­back as pan­cre­at­ic can­cer drug flops in PhII

Mo­men­ta Phar­ma­ceu­ti­cals has been hit with a set­back. The Cam­bridge, MA-based biotech says that its Phase II study match­ing the ex­per­i­men­tal necu­paranib with Abrax­ane and gem­c­itabine failed to make an ap­pre­cia­ble dent in metasta­t­ic pan­cre­at­ic can­cer.

At the halfway point of the study, with 57 deaths, the da­ta mon­i­tor­ing com­mit­tee de­cid­ed that they weren’t see­ing any ev­i­dence that the drug was mak­ing a sig­nif­i­cant dif­fer­ence for pa­tients. Now they’re shut­ting the study down and un­blind­ing the da­ta to see what the next best step will be for the pa­tients who are left.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.